CLINICAL AND PATHOGENETIC FEATURES OF MUSCLE SYMPTOMS AGAINST THE BACKGROUND OF THERAPY WITH STATINS IN PATIENTS WITH COMPENSATED HYPOTHYROIDISM


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Acesso é pago ou somente para assinantes

Resumo

The article presents the results of the evaluation of the frequency of muscle symptoms and their interrelations with biochemical markers of muscle damage in persons on statin therapy in the presence or absence of compensated hypothyroidism. The three groups of 40 women in each group were compared. The main group included patients with compensated hypothyroidism receiving statin therapy. Control groups included persons without thyroid pathology with statin therapy and patients with compensated hypothyroidism without statin therapy. The characteristics of muscle pain and weakness were assessed according to standard questionnaires, and biochemical markers of muscle damage. Muscle pain (p=0.0006) with typical localization for statin-induced myopathy (SIM) was more often observed in the main group, with greatest negative impact on daily motor activity in the form of walking ability (p=0.0033), and there was a significant increase in creatinine phosphokinase levels (p=0.012). Reliable direct correlations of muscle pain with the levels of biochemical markers of myopathies and the duration of use of statins was found only in the main group. In both control groups, muscle symptoms were closely related to the presence of concomitant pathology (vertebrogenic syndromes, chronic venous insufficiency). As a result of the study, it was revealed that patients with compensated hypothyroidism receiving statin therapy have increased frequency of muscle pain with typical for SIM localization, pathogenetically associated with myocyte damage. There is a need to monitor clinical and biochemical signs of muscle tissue damage in patients with compensated hypothyroidism receiving statins.

Texto integral

Acesso é fechado

Sobre autores

L. Lugovaya

FSBEI HE "Nizhny Novgorod State Medical Academy" of RMH

Email: liya.lugovaya@inbox.ru
Teaching Assistant at the Department of Endocrinology and Internal Diseases Nizhny Novgorod

L. Strongin

FSBEI HE "Nizhny Novgorod State Medical Academy" of RMH

Nizhny Novgorod

T. Nekrasova

FSBEI HE "Nizhny Novgorod State Medical Academy" of RMH

Nizhny Novgorod

Bibliografia

  1. Карпов Ю.А., Булкина О.С. Европейские рекомендации по лечению дислипидемий. Липидснижающая терапия у пациентов с острым коронарным синдромом и чрескожными коронарными вмешательствами. Мед. совет 2016;17:18-23.
  2. Григоричева Е.А., Евдокимов В.В. Фармакогенетические методы в оценке риска осложнений терапии статинами. Непрерывное медицинское образование и наука. 2016;11(1):32-5.
  3. Аронов Д.М., Арабидзе Г.Г., Ахмеджанов Н.М. и др. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. Российские рекомендации. Росс. кардиол. журн. 2017.
  4. Fulcher J., O'Connell R., Voysey M., et al. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015;385:1397-405.
  5. Драпкина О.М., Чернова Е.М., Корнеева О.Н. Статины и миопатия: молекулярные механизмы. Рациональная фармакотерапия в кардиологии. 2012;8(3):469-73.
  6. Smithson J. Drug induced muscle disorders. Clin. update. 2009;28(12):1056-62.
  7. Mancini G.B., Tashakkor A.Y., Baker S., Bergeron J., Fitchett D., Frohlich J., Genest J., Gupta M., Hegele R.A., Ng D.S., Pearson G.J., Pope J. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can. J. Cardiol. 2013; 29:1553-68.
  8. Vrablik M., Zlatohlavek L., Stulc T., Adamkova V., Prusikova M., Schwarzova L., Hubacek J.A., Ceska R. Statin-Associated Myopathy: From Genetic Predisposition to Clinical Management. Physiol. Res. 2014;63(3):327-34.
  9. Reiner Z., Catapano A.L., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS Guidelines for the management of dyslipidaemia. Eur. Heart J. 2011;32(14):1769-818.
  10. Фадеев В.В. Современные принципы диагностики и лечения гипотиреоза. Земский врач. 2010;2:13-6.
  11. Волкова А.Р., Дора С.В., Беркович О.А. и др. Субклинический гипотиреоз - новый фактор сердечно-сосудистого риска. Терапия. 2016;10(6):23-8.
  12. Вербовой А.Ф., Шаронова Л.А., Косарева О.В. и др. Гипотиреоз и сердечно-сосудистые заболевания. Фарматека. 2015;310(17):36-7.
  13. Некрасова Т.А., Стронгин Л.Г., Леденцова О.В. и др. Взаимосвязь между уровнем ТТГ и некоторыми факторами сердечно-сосудистого риска при аутоиммунном тиреоидите и субклиническом гипотиреозе. Клин. и эксперим. тиреоидол. 2014;10(2):16-21.
  14. Волкова А.Р., Красильникова Е.И., Дора С.В. и др. Показатели липидного спектра крови и функциональное состояние щитовидной железы у больных ишемической болезнью сердца. Вест. Росс. военно-медицинской академии. 2009;3(27):88-91.
  15. Bruckert E., Hayem G., Dejager S., et al. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the Primo study. Cardiovascular Drugs and Therapy. 2006;19(6):403-14.
  16. Robinson C.D., Bair TL., Horne B.D., et al. Hypothyroidism as a risk factor for statin intolerance. J. Clin. Lipidol. 2014;8(4):401-7.
  17. Zhang H., Plutzky J., Skentzos S., Morrison F., Mar P, Shubina M., Turchin A. Discontinuation of statins in routine care settings: a cohort study. Ann. Int. Med. 2013;158:526-34.
  18. Cleeland S.C., Ryan K.M. Pain assessment: global use of Brief Pain Inventory. Ann. Acad. Med. 1994;23(2):129-38.
  19. Харченко Ю.А. Адекватная оценка боли - залог ее успешного лечения. Universum: Медицина и фармакология. Электронный журнал. 2014;5(4);1-16.
  20. Damush T.M., Wu J., Bair M.J., et al. Self-management practices among primary care patients with musculoskeletal pain and depression. J. Behav. Med. 2008;31(4):301-7.
  21. Babic-Naglic D. The diagnostics of chronic musculoskeletal pain. Reum. 2007;54(2):32-6.
  22. Kapstad H., Rokne B., Stavern K. Psychometric properties of the Brief Pain Inventory among patient with osteoarthritis undergoing total hip replacement surgery. Health Qual. Life Outcomes. 2010;8:148.
  23. Cleeland S.C. The Brief Pain Inventory. User guide. 2009.
  24. Новик A.A., Ионова Т.И. Руководство по исследованию качества жизни в медицине. СПб., М., 2002.
  25. Mendoza Т., Wang X.S., Cleeland C.S., Morrissey М., Johnson В.А., Wendt J.K., Huber S.L. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer. 1999;85:1186-96.
  26. Shuman-Paretsky M.J., Belser-Ehrlich J., Holtser R. Psychometric properties of Brief Fatigue Inventory in community dwelling older adults. Arch. Phys. Med. Rehabih. 2014;95(8):1533-39.
  27. Abdulrazaq M., Hamdan F., Al-Tameemi W. Electrophysiologic and clinico-pathologic characteristics of statin-induced muscle injury. Iran. J. Basic. Med. Sei. 2015;18(8):737-44.
  28. Abe Y., Miyashita M., Ito N., Shirai Y., Momose Y., Ichikawa Y., Tsuji S., Kazuma K. Attitude of outpatients with neuromuscular diseases in Japan to pain and use of analgesics. J. Neurol. Sei. 2008;267(1-2):22-7.
  29. Петров A.B., Луговая Л.A., Стронгин Л.Г., Некрасова Т.А. Недиагностированный гипотиреоз - фактор риска возникновения рабдомиолиза при терапии статинами. Клин, и эксперим. тиреоидол. 2014;10(4):26-33.
  30. Bitzur R., Cohen H., Kamari Y., Harats D. Intolerance to statins: Mechanisms and management. Diabetes Care. 2013;36(Suppl. 2):325-30.
  31. Затейщиков Д.А. Проблемы безопасности стати-нов. Фарматека. 2005;(8):75-8.

Arquivos suplementares

Arquivos suplementares
Ação
1. JATS XML
Baixar

Declaração de direitos autorais © Bionika Media, 2017

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies